Clinical Trial Applications: Filter, Search, and view applications
| # | Protocol No | Study Title | Investigator(s) & Site(s) | |
|---|---|---|---|---|
81. |
ECCT/21/12/05 | 131 Inclacumab Ph 3 Trial. A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vasoocclusive Crises |
Principal Investigator(s) 1. Bernhards Ragama Ogutu 2. Fredrick Asirwa Chite 3. Videlis N Nduba 4. Prof. Jessie N Githanga Site(s) in Kenya 1. Strathmore University Medical Centre (Nairobi City county) 2. KEMRI/CRDR (Nairobi City county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. Gertrude’s Children’s Hospital. (Nairobi City county) 5. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) |
View |
82. |
ECCT/21/11/08 | GBT_131 Inclacumab-Ps 3 Trial. A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises |
Principal Investigator(s) 1. Videlis N Nduba 2. Prof. Jessie N Githanga 3. Fredrick Sirwa Chite 4. Bernhards Ragama Ogutu Site(s) in Kenya 1. KEMRI/CRDR (Nairobi City county) 2. KEMRI Siaya Clinical Research Annex (Siaya county) 3. Gertrude’s Children’s Hospital. (Nairobi City county) 4. Strathmore University Medical Centre (Nairobi City county) 5. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) |
View |
83. |
ECCT/21/11/07 | lidERA A PHASE III, RANDOMIZED, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE EFFICACY AND SAFETY OF ADJUVANT GIREDESTRANT COMPARED WITH PHYSICIAN'S CHOICE OF ADJUVANT ENDOCRINE MONOTHERAPY IN PATIENTS WITH ESTROGEN RECEPTORPOSITIVE, HER2-NEGATIVE EARLY BREAST CANCER |
Principal Investigator(s) 1. Fredrick Asirwa Chite Site(s) in Kenya 1. International Cancer Institute (ICI) (Uasin Gishu county) 2. Aga Khan University Hospital (Nairobi City county) |
View |
84. |
ECCT/21/11/04 | GBT_131 Inclacumab-Ps 3 Trial. A Randomized, Double-blind, Placebo-controlled, Multicenter Study to Assess the Safety and Efficacy of Inclacumab in Participants with Sickle Cell Disease Experiencing Vaso-occlusive Crises |
Principal Investigator(s) 1. Fredrick Sirwa Chite 2. Prof Jessie N Githanga 3. Bernhards Ragama Ogutu 4. Videlis N Nduba Site(s) in Kenya 1. International Cancer Institute (ICI)-Eldorate (Uasin Gishu county) 2. KEMRI/CRDR (Nairobi City county) 3. KEMRI Siaya Clinical Research Annex (Siaya county) 4. Gertrude’s Children’s Hospital. (Nairobi City county) 5. Strathmore University Medical Centre (Nairobi City county) |
View |
85. |
ECCT/21/11/01 | VAT 00008 A parallel-group, Phase III, multi-stage, modified double-blind, multi-armed study to assess the efficacy, safety, and immunogenicity of two SARS-CoV-2 Adjuvanted Recombinant Protein Vaccines (monovalent and bivalent) for prevention against COVID-19 in adults 18 years of age and older |
Principal Investigator(s) 1. Walter Godfrey Jaoko Site(s) in Kenya 1. Kenya Medical Research Institute (Kisumu county) 2. KEMRI/Walter Reed Project Research Center (Kericho county) 3. KEMRI/CCR Partners in Health R&D (PHRD) (Kiambu county) 4. KEMRI CMR (Kisumu county) 5. Kenya Medical Research Institute (Nairobi City county) 6. KEMRI-UAMRD-A/K, Kombewa Clinical Research Center (Kisumu county) 7. Moi University Clinical Research Centre (Uasin Gishu county) 8. Aga Khan University Hospital (Nairobi City county) 9. KEMRI CCR-Butere County Hospital Site (Kakamega county) 10. Ganjoni Clinic (Mombasa county) |
View |